Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Sep
26
2016
Vanda v. Roxane Labs. – Are Two Natural Laws Better Than One? Schwegman, Lundberg & Woessner, P.A.
Jan
11
2024
Federal March-In Rights Meet Clawbacks – The Future of 35 USC ss. 200-212 Schwegman, Lundberg & Woessner, P.A.
Sep
26
2012
Akami/McKesson Decision Re-defines Induced Infringement Schwegman, Lundberg & Woessner, P.A.
Jan
26
2018
Chinese Team Reports Cloning Two Monkeys Using the Same Nuclear Donor – But Don’t Try to Patent Them! Schwegman, Lundberg & Woessner, P.A.
Feb
22
2013
Supreme Court Hears “Replicant Soy Bean” Appeal Schwegman, Lundberg & Woessner, P.A.
Jun
13
2013
Supreme Court Rules In Myriad On Patentability Of DNA Schwegman, Lundberg & Woessner, P.A.
Sep
3
2013
Dr. Watson, Genomics and the Law Schwegman, Lundberg & Woessner, P.A.
Nov
11
2021
Beijing Intellectual Property Court Accepts China’s First Drug Patent Linkage Litigation Case Schwegman, Lundberg & Woessner, P.A.
Dec
2
2013
The Unacknowledged Role of Section 112 in the Myriad Decisions Re: Patent Eligibility of Genomic DNA Schwegman, Lundberg & Woessner, P.A.
Sep
11
2014
Indefiniteness After The Supreme Court Nautilus Decision – A Very “Delicate Balance” Schwegman, Lundberg & Woessner, P.A.
Oct
7
2023
The Tyranny of Large Numbers: Their Grip on s. 102 Inquiries Schwegman, Lundberg & Woessner, P.A.
Jun
3
2020
Chinese Patent Application for Coronavirus Vaccine Published Schwegman, Lundberg & Woessner, P.A.
Feb
14
2021
Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear Schwegman, Lundberg & Woessner, P.A.
Jan
10
2022
Novartis v. Accord – No Limits on Negative Limitations? Schwegman, Lundberg & Woessner, P.A.
Dec
6
2013
Australia – High Court Decision on Methods of Medical Treatment Schwegman, Lundberg & Woessner, P.A.
Sep
11
2014
FDA Publishes “Purple Book” for Biologicals/Biosimilars Schwegman, Lundberg & Woessner, P.A.
Nov
5
2014
Genetic Technologies v. Bristol Myers – 101 At Work Schwegman, Lundberg & Woessner, P.A.
Jul
7
2019
Federal Circuit Denies En Banc Review of Athena v. Mayo Schwegman, Lundberg & Woessner, P.A.
May
21
2015
Apotex Petitions Supreme Court to Review Therasense Standards Schwegman, Lundberg & Woessner, P.A.
Dec
31
2022
China to Remove Infringing Pharmaceuticals from Procurement Platforms Schwegman, Lundberg & Woessner, P.A.
Aug
27
2019
Nalproprion v. Actavis: WDR met by Substantially Equivalent Claim Elements(?) Schwegman, Lundberg & Woessner, P.A.
Sep
30
2015
Shire v. Amneal Pharma – Adjusting the Rearview Mirror Schwegman, Lundberg & Woessner, P.A.
Jun
26
2023
Does the “Patent Eligibility Restoration Act of 2023” Revive Diagnostic Claims? Schwegman, Lundberg & Woessner, P.A.
Oct
12
2020
Biogen v. EMD Serono – “A Nest of Limitations” Schwegman, Lundberg & Woessner, P.A.
Mar
26
2012
Patent and Trademark Office (PTO) To Biotech Examiners – We’ll Get Back To You! Schwegman, Lundberg & Woessner, P.A.
Sep
19
2022
US Department of Labor Awards $3M to Support Project to Improve Working Conditions in Bangladesh, Focused on Labor Rights Abuses in Three Cities U.S. Department of Labor
Jul
3
2012
Compensation for Energy Workers, $8 Billion and Counting U.S. Department of Labor
Sep
29
2014
3 Ways to Protect Our Farmers This Fall U.S. Department of Labor
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins